ES2437108T3 - Tetrahidroazolopirazinas sulfoniladas y su utilización como productos médicos - Google Patents
Tetrahidroazolopirazinas sulfoniladas y su utilización como productos médicos Download PDFInfo
- Publication number
- ES2437108T3 ES2437108T3 ES10708496.4T ES10708496T ES2437108T3 ES 2437108 T3 ES2437108 T3 ES 2437108T3 ES 10708496 T ES10708496 T ES 10708496T ES 2437108 T3 ES2437108 T3 ES 2437108T3
- Authority
- ES
- Spain
- Prior art keywords
- aryl
- heteroaryl
- cycloalkyl
- alkyl
- alkylene group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuesto de fórmula general I donde a representa 1 o 2; b representa 0, 1 o 2; B representa C(R6a)(R6b), NR7, O o un enlace simple, con la condición de que si b es igual a 0,B no es NR7; W1, W2 y W3 representan, independientemente entre sí, CR5 o N, con la condición de que al menosuno de W1, W2 y W3 represente CR5; R1 representa arilo, heteroarilo, CH(arilo)2 o un arilo o heteroarilo unido a través de un grupoalquileno(C1-3); R2a, R2b, R3a, R3b, R6a y R6b representan, independientemente entre sí, H, F, Cl, Br, I, -CF3, OH, SH,O-alquilo(C1-6), alquilo(C1-6), cicloalquilo(C3-8), arilo o heteroarilo; o un cicloalquilo(C3-8), arilo oheteroarilo unido a través de un grupo alquileno(C1-6) o alquenileno(C2-6); y/o R2a y R2b y/o R3a y R3bpueden representar juntos >=O; R4 representa de 0 a 4 sustituyentes seleccionados, independientemente entre sí, entre F; Cl; OH; >=O; alquilo(C1-6); O-alquilo(C1-6); cicloalquilo(C3-8); arilo o heteroarilo; cicloalquilo(C3-8), arilo oheteroarilo unidos a través de un grupo alquileno(C1-6); y/o dos sustituyentes adyacentes de estos 0a 4 sustituyentes R4 forman un arilo o hereroarilo condensado; R5 representa H, alquilo(C1-6), halógeno, -CN o CF3; R7 representa H, alquilo(C1-6), cicloalquilo(C3-8), arilo, heteroarilo o cicloalquilo(C3-8), arilo oheteroarilo unido a través de un grupo alquileno(C1-6), alquenileno(C2-6) o alquinileno(C2-6);s >= 0 o 1, t >= 0, 1, 2 o 3, R8 representa H; alquilo(C1-6); cicloalquilo(C3-8); arilo o heteroarilo; cicloalquilo(C3-8), arilo oheteroarilo unidos a través de un grupo alquileno(C1-6); R9a y R9b representan, independientemente entre sí, H; F; Cl; OH; alquilo(C1-6); O- alquilo(C1-6); cicloalquilo(C3-8); arilo o heteroarilo; cicloalquilo(C3-8), arilo o heteroarilo unidos a través de un grupoalquileno(C1-6).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09003075 | 2009-03-04 | ||
EP09003075 | 2009-03-04 | ||
PCT/EP2010/001299 WO2010099938A1 (en) | 2009-03-04 | 2010-03-03 | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2437108T3 true ES2437108T3 (es) | 2014-01-08 |
Family
ID=40716949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10708496.4T Active ES2437108T3 (es) | 2009-03-04 | 2010-03-03 | Tetrahidroazolopirazinas sulfoniladas y su utilización como productos médicos |
Country Status (16)
Country | Link |
---|---|
US (1) | US8158628B2 (es) |
EP (1) | EP2403854B1 (es) |
JP (1) | JP2012519196A (es) |
CN (1) | CN102341398A (es) |
AR (1) | AR075539A1 (es) |
AU (1) | AU2010220561A1 (es) |
BR (1) | BRPI1010533A2 (es) |
CA (1) | CA2754330A1 (es) |
ES (1) | ES2437108T3 (es) |
HK (1) | HK1160450A1 (es) |
IL (1) | IL214911A0 (es) |
MX (1) | MX305105B (es) |
PL (1) | PL2403854T3 (es) |
RU (1) | RU2011140061A (es) |
TW (1) | TW201035102A (es) |
WO (1) | WO2010099938A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR082890A1 (es) * | 2010-09-03 | 2013-01-16 | Gruenenthal Gmbh | Derivados sustituidos de tetrahidropirrolopirazina |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
MA37756B1 (fr) | 2012-06-13 | 2018-09-28 | Hoffmann La Roche | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
EP3590940B1 (en) | 2012-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
CN103113324B (zh) * | 2013-02-07 | 2015-08-05 | 浙江工业大学 | 一种n-磺酰基取代的四氢吡咯类化合物的制备方法 |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
TW201605859A (zh) | 2013-11-14 | 2016-02-16 | 必治妥美雅史谷比公司 | 作為酪蛋白激酶1δ/ε抑制劑之新穎經取代之吡唑并-哌 |
MA38982A1 (fr) | 2013-11-26 | 2017-09-29 | Hoffmann La Roche | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl |
CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
MX2016010675A (es) | 2014-03-26 | 2016-11-10 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
CN108026077B (zh) | 2015-09-04 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 苯氧基甲基衍生物 |
MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | デュアルatx/ca阻害剤としての新規な二環式化合物 |
WO2017050792A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
MA42923A (fr) | 2015-09-24 | 2021-04-28 | Hoffmann La Roche | Composés bicycliques comme inhibiteurs mixtes de atx/ca |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
MA49879A (fr) | 2017-03-16 | 2020-06-24 | Hoffmann La Roche | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca |
CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563793B2 (en) * | 2004-12-20 | 2009-07-21 | Wyeth | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents |
WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
MX2008013599A (es) * | 2006-04-21 | 2008-10-31 | Smithkline Beechman Corp | Antagonistas del receptor il-8. |
WO2007140383A2 (en) | 2006-05-30 | 2007-12-06 | Neurogen Corporation | Spirocyclic sulfonamides and related compounds |
SI2066659T1 (sl) | 2006-09-29 | 2013-10-30 | Grunenthal Gmbh | Substituirani sulfonamidni derivati |
WO2008046573A1 (de) | 2006-10-16 | 2008-04-24 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
CN101686989B (zh) * | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | 取代的咪唑并杂环 |
-
2010
- 2010-02-26 TW TW099105566A patent/TW201035102A/zh unknown
- 2010-03-03 JP JP2011552360A patent/JP2012519196A/ja not_active Withdrawn
- 2010-03-03 ES ES10708496.4T patent/ES2437108T3/es active Active
- 2010-03-03 RU RU2011140061/04A patent/RU2011140061A/ru not_active Application Discontinuation
- 2010-03-03 CN CN2010800106612A patent/CN102341398A/zh active Pending
- 2010-03-03 EP EP10708496.4A patent/EP2403854B1/en not_active Not-in-force
- 2010-03-03 MX MX2011008864A patent/MX305105B/es active IP Right Grant
- 2010-03-03 WO PCT/EP2010/001299 patent/WO2010099938A1/en active Application Filing
- 2010-03-03 AU AU2010220561A patent/AU2010220561A1/en not_active Abandoned
- 2010-03-03 CA CA2754330A patent/CA2754330A1/en not_active Abandoned
- 2010-03-03 BR BRPI1010533A patent/BRPI1010533A2/pt not_active IP Right Cessation
- 2010-03-03 PL PL10708496T patent/PL2403854T3/pl unknown
- 2010-03-04 AR ARP100100647A patent/AR075539A1/es not_active Application Discontinuation
- 2010-03-04 US US12/717,625 patent/US8158628B2/en not_active Expired - Fee Related
-
2011
- 2011-09-01 IL IL214911A patent/IL214911A0/en unknown
-
2012
- 2012-01-26 HK HK12100745.4A patent/HK1160450A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1160450A1 (en) | 2012-08-17 |
WO2010099938A1 (en) | 2010-09-10 |
US8158628B2 (en) | 2012-04-17 |
IL214911A0 (en) | 2011-11-30 |
MX2011008864A (es) | 2011-09-15 |
PL2403854T3 (pl) | 2014-02-28 |
CN102341398A (zh) | 2012-02-01 |
BRPI1010533A2 (pt) | 2016-03-15 |
RU2011140061A (ru) | 2013-04-10 |
TW201035102A (en) | 2010-10-01 |
JP2012519196A (ja) | 2012-08-23 |
EP2403854A1 (en) | 2012-01-11 |
AR075539A1 (es) | 2011-04-20 |
US20100234387A1 (en) | 2010-09-16 |
AU2010220561A1 (en) | 2011-10-27 |
CA2754330A1 (en) | 2010-09-10 |
MX305105B (es) | 2012-11-12 |
EP2403854B1 (en) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2437108T3 (es) | Tetrahidroazolopirazinas sulfoniladas y su utilización como productos médicos | |
RU2015145784A (ru) | Способ получения циклоалкилкарбоксамидо-индольных соединений | |
RU2014117188A (ru) | Способ получения производных 4,4-дифтор-3,4-дигидроизохинолина | |
CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
CY1122350T1 (el) | Μεθοδος παρασκευης ινγενολ-3-αγγελικου | |
BR112013001267A2 (pt) | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro | |
ATE495175T1 (de) | Naphthyridinderivate als kaliumkanalmodulatoren | |
BR112012020986A2 (pt) | composto de amina cíclica e acaricida | |
MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
CR20130129A (es) | Anàlogos de buprenorfina | |
CR20140237A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
RS52872B (en) | PIRAL UNITS | |
CR20120295A (es) | Triazolopiridinas | |
AR091145A1 (es) | Tioamidas de acido n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxilico y su uso como herbicidas | |
CR20120637A (es) | Triazolopiridinas sustituidas | |
EA201590979A1 (ru) | Способы и промежуточные химические соединения для получения фармацевтических средств | |
CR20150661A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas | |
CY1113716T1 (el) | Νεα μεθοδος συνθεσης της αγομελατινης | |
AR090939A1 (es) | Sales de amidas de los acidos n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxilicos y su uso como herbicidas | |
CY1116540T1 (el) | Μεθοδος παραγωγης 2'-δεοξυ-5-αζακυτιδινης (δεσιταβινη) | |
RU2009131835A (ru) | Способ получения бетамиметиков | |
MA35086B1 (fr) | Compose de triazolopyridine | |
EA201992421A1 (ru) | Способ получения озанимода | |
BR122018074319B8 (pt) | Método para preparar um composto de fórmula 14 | |
RU2012148909A (ru) | Новый синтез соединений тиазолидиндиона |